INDOCO REMEDIES has announced its results for the year ended March 2018. Let us have a look at the detailed performance review of the company during FY17-18.
No. of Mths Year Ending | 12 Mar-17* | 12 Mar-18* | % Change | |
---|---|---|---|---|
Net Sales | Rs m | 10,748 | 10,419 | -3.1% |
Other income | Rs m | 40 | 47 | 18.1% |
Total Revenues | Rs m | 10,787 | 10,466 | -3.0% |
Gross profit | Rs m | 1,565 | 1,349 | -13.8% |
Depreciation | Rs m | 633 | 677 | 7.0% |
Interest | Rs m | 62 | 235 | 278.6% |
Profit before tax | Rs m | 909 | 484 | -46.8% |
Tax | Rs m | 139 | 72 | -47.8% |
Profit after tax | Rs m | 771 | 412 | -46.6% |
Gross profit margin | % | 14.6 | 12.9 | |
Effective tax rate | % | 15.3 | 15.0 | |
Net profit margin | % | 7.1 | 3.9 |
No. of Mths Year Ending | 12 Mar-17* | 12 Mar-18* | % Change | |
---|---|---|---|---|
Networth | Rs m | 6,513 | 6,750 | 3.6 |
Current Liabilities | Rs m | 3,904 | 4,157 | 6.5 |
Long-term Debt | Rs m | 1,323 | 1,233 | -6.8 |
Total Liabilities | Rs m | 11,968 | 12,363 | 3.3 |
Current assets | Rs m | 5,721 | 5,373 | -6.1 |
Fixed Assets | Rs m | 5,307 | 6,244 | 17.7 |
Total Assets | Rs m | 11,968 | 12,363 | 3.3 |
Particulars | No. of months | 12 | 12 | % Change |
---|---|---|---|---|
Year Ending | Mar-17 | Mar-18 | ||
Cash Flow from Operating Activities | Rs m | 886 | 1,227 | 38.4% |
Cash Flow from Investing Activities | Rs m | -1,706 | -1,360 | - |
Cash Flow from Financing Activities | Rs m | 1,316 | -388 | - |
Net Cash Flow | Rs m | 497 | -521 | - |
No. of Mths Year Ending | 12 Mar-17* | 12 Mar-18* | |
---|---|---|---|
Sales per share (Unadj.) | Rs | 116.6 | 113.1 |
TTM Earnings per share | Rs | 8.4 | 4.5 |
Diluted earnings per share | Rs | 8.4 | 4.5 |
Price to Cash Flow | x | 12.3 | 15.9 |
TTM P/E ratio | x | 286.6 | 286.7 |
Price / Book Value ratio | x | 4.3 | 3.4 |
Market Cap | Rs m | 17,283 | 17,287 |
Dividends per share (Unadj.) | Rs | 1.6 | 1.0 |
Current Ratio: The company's current ratio deteriorated and stood at 1.3x during FY18, from 1.5x during FY17. The current ratio measures the company's ability to pay short-term and long-term obligations.
Interest Coverage Ratio: The company's interest coverage ratio deteriorated and stood at 3.1x during FY18, from 15.6x during FY17. The interest coverage ratio of a company states how easily a company can pay its interest expense on outstanding debt. A higher ratio is preferable.
Return on Equity (ROE): The ROE for the company declined and down at 6.1% during FY18, from 11.8% during FY18. The ROE measures the ability of a firm to generate profits from its shareholders capital in the company.
Return on Capital Employed (ROCE): The ROCE for the company declined and down at 9.0% during FY18, from 12.4% during FY17. The ROCE measures the ability of a firm to generate profits from its total capital (shareholder capital plus debt capital) employed in the company.
Return on Assets (ROA): The ROA of the company declined and down at 5.2% during FY18, from 7.0% during FY17. The ROA measures how efficiently the company uses its assets to generate earnings.
No. of Mths Year Ending | 12 Mar-17* | 12 Mar-18* | |
---|---|---|---|
Current ratio | x | 1.5 | 1.3 |
Debtors’ Days | Days | 73 | 73 |
Interest coverage | x | 15.6 | 3.1 |
Debt to equity ratio | x | 0.2 | 0.2 |
Return on assets | % | 7.0 | 5.2 |
Return on equity | % | 11.8 | 6.1 |
Return on capital employed | % | 12.4 | 9.0 |
To see how INDOCO REMEDIES has performed over the last 5 years, please visit here.
Over the last one year, INDOCO REMEDIES share price has moved up from Rs 210.8 to Rs 187.6, registering a loss of Rs 23.2 or around 11.0%.
(To know more, check out historical annual results for INDOCO REMEDIES and quarterly results for INDOCO REMEDIES)
For the quarter ended December 2019, INDOCO REMEDIES has posted a net profit of Rs 93 m (up 74.9% YoY). Sales on the other hand came in at Rs 3 bn (up 10.2% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.
For the quarter ended September 2019, INDOCO REMEDIES has posted a net profit of Rs 73 m (up 194.1% YoY). Sales on the other hand came in at Rs 3 bn (up 23.9% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.
More Views on NewsMy new guide will show you the huge potential in future proof businesses.
The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.
The charts are telling the bulls to be cautious.
Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
Ajit Dayal on the investing strategy for 2021 and beyond.
More
| |
Equitymaster requests your view! Post a comment on "INDOCO REMEDIES 2017-18 Annual Report Analysis". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!